CXCL10/IP-10/CRG-2 Antibody (33008R) [Alexa Fluor® 532]

• Reactivity: Hu
• Applications: ELISA
• Clone: 33008R
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 532

CXCL10/IP-10/CRG-2 Antibody (33008R) [Alexa Fluor® 532] Summary

• Immunogen: E. coli-derived recombinant human CXCL10/IP-10/CRG-2
  Val22-Pro98
  Accession # P02778.2
• Specificity: Detects human CXCL10/IP-10/CRG-2 in direct ELISAs.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 degreesC as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL10/IP-10/CRG-2 Antibody (33008R) [Alexa Fluor® 532]

• C7
• chemokine (C-X-C motif) ligand 10
• CRG2
• CRG-2
• CXCL10
• gIP-10
• IFI10
• INP10
• IP-10
• mob-1
• SCYB10

Background

CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts and endothelial cells. It has since been shown that CXCL10 mRNA is also induced by LPS, IL-1 beta , TNF-alpha , IL-12, and viruses. Additional cell types that have been shown to express CXCL10 include activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. CXCL10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human CXCL10, CRG-2, has been cloned and shown to share approximately 67% amino acid sequence identity with human CXCL10. Human CXCL10 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted protein. The amino acid sequence of CXCL10 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CXCL10 has been shown to be a chemoattractant for activated T-lymphocytes. CXCL10 has been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent antitumor effect. A chemokine receptor specific for CXCL10 and Mig has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P02778.2()